in persons with RA found that 31% of their 115 person sample was cognitively impaired and stated that further studies should be done to identify the specific domain of cognitive function that is most commonly affected (1). In this project, I will be looking at and summarizing all the data and findings that have been collected and reported on in the RA population and seeing which domains of cognition differ and which do not differ when compared to the general population and aged based population norms.

**Objectives:** To screen autoantibodies of RA with high sensitivity and specificity using human proteome microarrays[2].

**Methods:** Firstly, a case-control method was used to analyze the serum antibodies of RA patients using human proteome microarray which composed of 20,000 proteins, and identified RA-related antibodies. Then, expanded the sample size and analyzed the expression of these candidates between RA patients and healthy controls.

**Results:** The serum of five RA patients and five healthy controls were selected to detect the RA-related autoantibodies by microarray, and 25 candidates were screened. Then the IgG and IgM RA-focused microarrays composed of the 25 proteins were screened with additional cohorts of 72 RA patients and 106 healthy controls. The results of IgG protein microarray showed: (1) Expression of these 25 autoantibodies in RA patients was significantly higher than those in healthy controls (P<0.05). (2) ROC analysis showed that the combination of anti-RBPJ, anti-SH3BGR and anti-PAFAH1B3 autoantibody can be highly RA-specific biomarkers, with 66.7% sensitivity and 74.2% specificity, and the area under the curve is 0.734; meanwhile the sensitivity and specificity of the anti-CCP antibody and RF-negative RA patients diagnosis were 77.8% and 65.6%, and the area under the curve was 0.720. The results of IgM protein microarray showed: (1) Only 10 out of the 25 candidates’ expression was significantly higher in RA patients than healthy controls (P<0.05). (2) Compared with anti-CCP antibody and/or RF-positive patients, the expression of anti-PAFAH1B3, anti-RBPJ, anti-SH3BGR, anti-UBAS, anti-ANP32A, anti-PAGE2, anti-SHFM1 and anti-PDE1B was found significantly higher in anti-CCP and RF-negative patients (P<0.05). (3) ROC analysis showed that anti-PAFAH1B3 antibody was identified to diagnose RA with 76.2% sensitivity and 72.9% specificity, and the area under the curve was 0.708; however, there were no significance for the diagnosis of anti-CCP antibody and RF-negative RA patients (P>0.15).

**Conclusion:** The combination of IgG-type antibodies anti-RBPJ, anti-SH3BGR and anti-PAFAH1B3, the IgM-type antibody anti-PAFAH1B3 as well, has high sensitivity and specificity for the diagnosis of RA; especially the IgG-type antibody combination has high value for the diagnosis of anti-CCP and RF-negative RA patients.

**REFERENCES**


**Acknowledgement:** This work was supported by grants from the National Natural Science Foundation of China (81771774) and the Anhui Provincial Natural Science Foundation (1708085MH191)

**Disclosure of Interests:** None declared


**HEMATOLOGICAL MARKERS OF SYSTEMIC INFLAMMATION CORRELATE WITH CLINICAL, LABORATORY AND ULTRASOUND DISEASE ACTIVITY PARAMETERS IN RHEUMATOID ARTHRITIS PATIENTS**

Bozena Targonska-Stepniak, Robert Zwolak, Mariusz Piotrowski, Maria Magdan. Medical University of Lublin, Department of Rheumatology and Connective Tissue Diseases, Lublin, Poland

**Background:** An accurate measurement of disease activity and inflammation is essential for customizing the most appropriate management and treatment strategy in patient with rheumatoid arthritis (RA). Current data show that hematological markers of systemic inflammation (peripheral blood neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR) and monocyte-to-lymphocyte (MRL) ratios) could be used as novel, sensitive measures of inflammatory response, additionally to conventional laboratory and clinical markers (erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Disease Activity Score of 28 joints (DAS28), tender joint count (TJC), swollen joint count (SJC)). The ultrasonography US) of joints enables the disease activity assessment by quantifying thickening and vascularity of the synovium.

**AB0284**

**IDENTIFICATION OF NEW AUTOANTIBODIES FOR RHEUMATOID ARTHRITIS USING HUMAN PROTEOME MICROARRAYS**

Li Lin1, Jinjui Tan2, Hong-Liang Zhang3, Yu-Jie Tang2, Li Xin-Ya3, Quan-Quan Lu1, Ya-Ling Wang1, Zi-Wen Zhu1. Anhui Medical University Affiliated Provincial Hospital, hefei, China; 1The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, hefei, China; 2Division of Life Sciences and Medicine, University of Science and Technology of China, hefei, China

**Background:** Rheumatoid arthritis is an autoimmune disease characterized by symmetrical small arthritis. Anti-cyclic citrullinated peptide antibodies and rheumatoid factor are commonly used to diagnose RA[1]. However, the early diagnosis of RA can often be challenging due to the presence of high levels of anti-CCP antibody and negative anti-CCP antibody or RF in some patients. Therefore, it is urgent to find autoantibodies with high sensitivity and specificity as diagnostic markers for RA.
Objectives: The goal of the study was to assess the relationship of NLR, PLR, MLR with the conventional disease activity markers (ESR, CRP, CCP, DAS28, TJC, SJC) and results of joints US, in patients with RA.

Methods: The study was conducted in the consecutive 72 patients with RA (60 women, 12 men), with the mean (SD) age 53.4 (8.9) and disease duration 16.8 (10.3) years. The following procedures were assessed for all patients: joint counts, DAS28, complete blood cell counts, ESR, CRP, US, of 24 small joints.

Results: The mean (SD) values of hematological markers were as follows: NLR 3.24 (2.7) (range 0.2-13.96); PLR 193.26 (88.3) (range 71.2-560.8); MLR 0.3 (0.16) (range 0.06-0.87). The mean values of NLR and PLR were significantly lower in patients with low (DAS28 >32) vs moderate-high (DAS28 >32) disease activity; respectively NLR 2.4 (1.7) vs 4.0 (3.2), p=0.004; PLR 168.7 (58.0) vs 215.8 (104.9), p=0.4. Hematological markers of systemic inflammation were significantly, positively correlated with clinical, laboratory and US markers of the disease activity. Significant correlations were found between: NLR and DAS28, TJC, SJC, ESR, CRP, vascularity of synovium in US; PLR and DAS28, TJC, SJC, ESR, CRP, vascularity and hypertrophy of synovium in US; MLR and DAS28, TJC, SJC, ESR, CRP, vascularity and hypertrophy of synovium in US. In multiple regression test significant correlations were confirmed for: NLR and SJC (p=0.008), ESR (p=0.001), PLR (p=0.001), vascularity of synovium in US (p=0.02); PLR and ESR (p=0.03), CRP (p=0.03); MLR and DAS28 (p=0.04), ESR (p=0.001), hypertrophy of synovium in US (p=0.02).

Conclusion: The results of the study suggest that hematological markers of systemic inflammation (NLR, PLR, MLR) may serve as reliable, inexpensive and effective measure of inflammation in RA. The strong association with US imaging is an attractive result because of its predictive value and usefulness in clinical practice.

Disclosure of Interests: Bozena Targonska-Stepniak, Speakers bureau: Sandoz, Berlin-Chemie, Robert Zwolak; None declared, Mariusz Piotrowski; None declared, Maria Majdan, Speakers bureau: MSD, UCB, Abbvie, Roche


AB0285

PREDICTORS OF UNACCEPTABLE PAIN, AND UNACCEPTABLE PAIN WITH LOW INFLAMMATION, IN EARLY RHEUMATOID ARTHRITIS

Anna Eberhard1, Tor Olsofson2,3, Lennart T.H. Jacobsson4, Carl Turesson1,3.

1Lund University, Rheumatology, Department of Clinical Sciences, Malmö, Malmö, Sweden; 2Lund University, Rheumatology, Department of Clinical Sciences, Lund, Lund, Sweden; 3Skåne University Hospital, Department of Rheumatology, Malmö, Sweden; 4 Sahlgrenska Academy at Gothenburg University, Department of Rheumatology and Inflammation Research, Gothenburg, Sweden

Background: Pain is a major symptom in many patients with rheumatoid arthritis (RA). In early RA, pain is usually due to active synovitis, but over the disease course some patients experience pain without elevated laboratory markers of inflammation.

Objectives: To investigate predictors of unacceptable pain, and unacceptable pain with low inflammation, in patients with early RA.

Methods: Consecutive patients with early RA (symptom duration <12 months), recruited in 1995-2005 from a defined area, were followed through 5 years. Patients were managed according to usual care, with no pre-specified treatment protocol. Pain was assessed using a visual analogue scale (VAS; 0-100 mm). Unacceptable pain was defined as VAS pain>40 based on the patient acceptable symptom state (PASS) (1), and low inflammation as CRP<10 mg/l (2). Baseline predictors of unacceptable pain, and of unacceptable pain with low inflammation, were evaluated using logistic regression analysis.

Results: A total of 233 patients with early RA (73% female, 57% anti-CCP positive, mean age 60 years, median symptom duration 7 months) were included. Of these, 179 attended the 5-year follow-up. At 5 years, 34% had unacceptable pain, and 23% had unacceptable pain with low inflammation. High VAS scores for pain and patient’s global assessment (PGA) at baseline were associated with unacceptable pain at 5 years (Table). There was a negative association between baseline swollen joint count (SJC28) and unacceptable pain at the 5 year follow-up. In multivariate logistic regression analysis including VAS PGA and SJC28, both had an impact on unacceptable pain after 5 years (adjusted odds ratios per standard deviation (SD), with 95% CI 1.78 (1.26-2.52) and 0.61 (0.40-0.90)), respectively. Anti-CCP positive patients with unacceptable pain were less likely to experience unacceptable pain with low inflammation at 5 years (Table).

AB0286

STATINS TO PREVENT RHEUMATOID ARTHRITIS (STAPRA TRIAL): CHALLENGES IN RECRUITMENT AND RETENTION

Laurent van Boheemen1, S.A. Turk1, van Beers-Tas1, W.H. Bos2, E.N. Griepp3, A. M. van Sijl1, Maarten Boers4, Michael Nurmohamed4, Dirkjan van Schaardenburg5.

1ARC Reade, Amsterdam, Netherlands; 2Sint Maartenskliniek, Nijmegen, Netherlands; 3Antonius Ziekenhuis, Sneek, Netherlands; 4ARC VUmc, Amsterdam, Netherlands; 5ARC AMC, Amsterdam, Netherlands

Background: Primary prevention may be possible in subjects at high risk to develop rheumatoid arthritis (RA). We designed a placebo controlled randomized trial to investigate if atorvastatin can halt RA development in persons at risk for this disease (STAPRA, Netherlands Trial Register NTR5265). A statin was chosen because these drugs reduce disease activity in RA (1), hyperlipidemia patients on statins have a lower risk for developing RA (2) and dyslipidemia increased the risk for RA in a sero-positive arthralgia cohort (3). We assumed that high risk-subjects would be attracted to this trial. However, we experienced severe difficulties with patient inclusion and treatment adherence.

Objectives: To explore difficulties with patient recruitment and retention.

Methods: The STAPRA study is a multicenter, 3-year, randomized, placebo controlled, double-blind clinical trial to assess the efficacy of atorvastatin 40 mg daily in delaying or preventing RA development in persons at high risk, defined by the presence of arthralgia and the presence of high titers of anti-citrullinated protein antibody (ACP) or presence of both ACPA and rheumatoid factor (RF). Eligible participants were ≥18 years, did not use lipid lowering agents and had no synovitis. Five centers participated. Our goal was to recruit 220 study subjects based on an expected risk reduction of 21%. The unexpected low recruitment rate prompted us to evaluate the reasons to decline participation or to discontinue the study drug prematurely.

Results: Details were available from the initiating center (Reade) and 1 participating center (Sint Maartenskliniek (SMK)). During a period of 36 months, 164 eligible patients were asked to participate of whom 58 patients (35%) consented. Most common reasons to decline were: unwillingness to use study medication (49%) and the feeling that participation was too time-consuming (14%). Fifty-four patients were randomized since 4 failed screening due to hyperlipidemia or seronegativity on repeated testing. Currently, 11 participants (20%) have developed arthritis. Twelve